Biohaven Pharma

91 articles with Biohaven Pharma

• Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares

  6/19/2019

  Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,046,511 common shares at the public offering price, less underwriting discounts and commissions

• Biohaven Announces Proposed Public Offering Of Common Shares - June 17, 2019

  6/17/2019

  Biohaven Pharmaceutical Holding Company Ltd. announced that it has commenced an underwritten public offering of $300 million of its common shares.

• Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP

  5/8/2019

  Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date

• Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms

  5/8/2019

  Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019

• Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms

  5/7/2019

  Secured Priority Review Voucher (PRV) enabling expedited regulatory review of rimegepant Zydis® ODT New Drug Application (NDA)

• Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience

  4/3/2019

  William "BJ" Jones joins Biohaven as Chief Commercial Officer, Migraine and Common Diseases

• Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine

  4/1/2019

  BHV-3500 is the first CGRP receptor antagonist drug candidate to be administered in an intranasal (IN) formulation in late stage testing and is Biohaven's second drug candidate from its NOJECTION™ migraine platform

• Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application

  3/18/2019

  Rimegepant Zydis orally disintegrating tablet (ODT) is Biohaven's lead oral CGRP receptor antagonist drug candidate from its NOJECTION™ migraine platform

• Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole

  3/14/2019

  Company Announces Expanded Data From Troriluzole Phase IIb/III Long-Term Extension Study Compared To Matched Natural History Cohort

• Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant

  3/13/2019

  -Biohaven remains on-track for new drug application (NDA) submission for rimegepant Zydis ODT and tablet formulation in 2Q2019

• Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results

  2/28/2019

  Positioned to submit New Drug Applications (NDA) for rimegepant Zydis ODT and tablet formulations for the acute treatment of migraine in 2Q2019

• Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy

  2/19/2019

  Biohaven Pharmaceutical Holding Company Ltd. announced that it received orphan drug designation from the U.S. Food and Drug Administration for its product candidate verdiperstat, a novel myeloperoxidase inhibitor, for the treatment of multiple system atrophy.

• Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist

  2/4/2019

  Phase 2 Efficacy Trial Start Planned for Second Quarter 2019

• Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy

  1/23/2019

  Biohaven Pharmaceutical Holding Company Ltd. announced the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO) inhibitor, which Biohaven is developing as a potential treatment for multiple system atrophy (MSA).

• Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China

  1/7/2019

  Rimegepant is the first small molecule, orally administered, calcitonin gene-related peptide (CGRP) receptor antagonist potentially being developed for both the acute and preventive treatment of migraine in China

• Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

  12/18/2018

  Biohaven Pharmaceutical Holding Company Ltd. announced today the closing of its underwritten public offering of 3,859,060 of its common shares, including the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $37.25 per share.

• Biohaven Announces Pricing of Public Offering of Common Shares at $37.25 Per Share

  12/13/2018

  Biohaven Pharmaceutical Holding Company Ltd. today announced the pricing of its underwritten public offering of 3,355,705 of its common shares at a price to the public of $37.25 per share.

• Biohaven Announces Proposed Public Offering of Common Shares

  12/11/2018

  Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.

• Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study

  12/10/2018

  Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine

• Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

  12/3/2018

  Single dose, proprietary, rimegepant Zydis ODT formulation provided rapid onset of pain relief with numerical separation from placebo as early as 15 minutes and statistically significant by 60 minutes